# Tirzepatide without insurance: what drives the cost

> Paying cash for tirzepatide means weighing acquisition price, treatment duration, product format, clinical follow-up and product source, drawing on FDA, NIDDK, published economic analyses and drug references.

AthleticsMD Clinical Desk · 2026-10-05 · https://blog.athleticsmd.org/tirzepatide-without-insurance-what-drives-the-cost

Without insurance, the cost of tirzepatide depends on five drivers. The first is the drug's acquisition price, which economic evaluations treat as central to its value compared with lower-cost agents. The second is how long treatment continues: obesity is managed as a chronic disease, and some weight is likely to return after stopping. The third is the strength and format prescribed. The fourth is the clinical care needed to start, monitor and reassess therapy. The fifth is the product's source, because unapproved and compounded versions are not reviewed by the FDA before marketing [1, 2, 3, 4, 6, 7]. Coverage is not uniform: some, but not all, insurance plans cover medications for overweight and obesity, and NIDDK advises contacting the insurer to confirm [1].

## What tirzepatide is and who it is for

Tirzepatide is a GIP and GLP-1 agonist; GLP-1 stands for glucagon-like peptide-1, and the FDA groups these products as GLP-1 receptor agonists [2, 6, 7]. Under the brand name Mounjaro, it is used to lower blood sugar in type 2 diabetes and to lower the risk of heart attack, stroke or cardiovascular death in people with type 2 diabetes at high risk [6]. Under the brand name Zepbound, it is used for long-term weight management and for moderate to severe obstructive sleep apnea in people with obesity [7]. Both are given as a weekly injection under the skin [6, 7]. Tirzepatide (Zepbound) is one of six drugs the FDA has approved for long-term weight management [1].

Body mass index (BMI) is a measure of weight in relation to height, and clinicians use it to help decide whether a weight management medication may help [1]. NIDDK describes candidates as adults with a BMI of 30 or greater, or a BMI of 27 or greater with weight-related problems such as high blood pressure or type 2 diabetes [1]. NIDDK also states that these medications are not for everyone with a high BMI and do not replace healthy eating and physical activity [1].

## Driver 1: acquisition price

The most detailed US analysis in this set is a lifetime cost-effectiveness study in JAMA Health Forum, which used a validated microsimulation model that runs individual-level simulations to project long-term outcomes [4]. Its population came from 4823 participants in the 2017-2020 National Health and Nutrition Examination Survey, representing 126 million US adults aged 20 to 79 who would meet clinical trial criteria for antiobesity medications [4]. Their mean age was 48 years, 51% were female, mean BMI was 34.7, and 85% had at least one weight-related comorbidity [4].

The model measured outcomes in quality-adjusted life-years (QALYs) and reported incremental cost-effectiveness ratios (ICERs), expressed in dollars per QALY, comparing tirzepatide plus lifestyle modification with lifestyle modification alone [4]. Tirzepatide produced 0.35 incremental QALYs, the largest gain of the four drugs modeled, at an ICER of $197 023 per QALY [4]. To reach a $100 000 per QALY threshold, tirzepatide's price would need a further 30.5% discount from current net prices [4]. At current net prices, it had a 0% probability of being cost-effective across thresholds from $100 000 to $200 000 per QALY [4].

The same model projected these lifetime health effects per 100 000 people [4]:

- 45 609 obesity cases averted (95% uncertainty interval 45 092-46 126) [4].
- 20 854 fewer diabetes cases (95% UI 19 432-22 276) [4].
- 10 655 fewer cardiovascular disease cases (95% UI 10 124-11 186) [4].

Costs were expressed in 2023 US dollars, and future costs and QALYs were discounted at 3% a year; the analysis addresses population-level value rather than any individual's pharmacy price [4]. The authors concluded that tirzepatide offered substantial long-term health benefits but was not cost-effective at current net prices [4].

A 2026 systematic literature review of 26 economic evaluations, which used a narrative synthesis and is listed here as a narrative review, provides background [3]. All included studies came from high- or upper-middle-income countries, mostly from payer perspectives, and results were heterogeneous and sensitive to model assumptions [3]. The review reported that tirzepatide produced greater health gains with frequently favourable ICERs but often exceeded willingness-to-pay thresholds in lower-threshold settings, while phentermine/topiramate appeared economically competitive largely because of lower acquisition costs [3]. The authors called for clearer distinctions between cost-effectiveness and affordability [3].

## Driver 2: how long treatment lasts

NIDDK describes obesity as a chronic disease, and a clinician may advise staying on medication indefinitely if weight loss improves health without serious side effects [1]. NIDDK also states that people will probably regain some weight after stopping [1]. Most weight loss occurs within the first 6 months, and if a person has not lost at least 5% of starting weight after 12 weeks on the full dose, the clinician will probably advise stopping [1]. The JAMA model varied treatment discontinuation rates in its scenario analyses [4].

## Driver 3: strength and format

Tirzepatide is listed in six strengths, from 2.5 mg to 15 mg, supplied as single-dose pens, multi-dose KwikPens, and single-dose or multi-dose vials [6, 7]. Storage and discard rules limit how long each supply can be used [7]:

- Single-dose pens and vials may be kept at room temperature for up to 21 days in total and are then discarded [7].
- KwikPens and multi-dose vials are discarded at whichever comes first: 30 days after first use, 4 weekly doses, or 30 total days at room temperature [7].

For compounded GLP-1 products dispensed in multi-dose vials, the FDA recommends discarding the vial within 28 days after first use, even if medication remains [2]. Neither drug reference lists prices by strength or format [6, 7].

## Driver 4: the clinical care around the drug

NIDDK lists the factors in choosing a medication as likely benefits, possible side effects, current health issues and other medications, family medical history, and cost [1]. Several features of tirzepatide can call for follow-up care [6, 7]:

- Doses of other diabetes medicines may need to change because of low-blood-sugar risk with insulin or sulfonylureas [6].
- People with diabetic retinopathy, a diabetes-related eye condition, are advised to keep appointments for vision checks [6, 7].
- Clinicians need to know about procedures under anesthesia or deep sedation because of aspiration risk [7].
- People taking birth control pills may be advised to use another method for 4 weeks after starting and after each dose increase [6].

NIDDK also notes that these medications work best when combined with a lifestyle program [1].

## Driver 5: product source and regulatory review

The FDA states that unapproved versions of GLP-1 drugs, including tirzepatide, do not undergo FDA review for safety, effectiveness or quality before marketing, and that compounded drugs should be used only in patients whose medical needs cannot be met by an FDA-approved drug [2]. As of May 31, 2026, the FDA had received more than 730 adverse event reports associated with compounded tirzepatide; these are likely underreported, and causation cannot always be determined [2]. The agency has also documented other problems [2]:

- Adverse event reports that may relate to dosing errors with compounded semaglutide, and to compounded semaglutide or tirzepatide prescribed beyond approved label doses [2].
- Compounded GLP-1 shipments that arrived warm or with inadequate ice packs [2].
- Fraudulent labels naming pharmacies that did not make the product [2].
- Products falsely sold "for research purposes" [2].

An editorial in the Journal of General Internal Medicine states that patients with clinical indications often struggle to obtain these medications because of shortages and high costs, and separately that unregulated alternatives such as compounded injections introduce safety risks [5].

The FDA's telehealth red flags include the following [2]:

- Deep discounts or prices that seem too good to be true [2].
- No screening and prescription by a licensed doctor [2].
- No licensed doctor available after the medication arrives [2].
- Damaged packaging, missing instructions, label spelling errors or incorrect pharmacy addresses [2].

## Where AthleticsMD fits, and where another route may fit better

AthleticsMD offers ShredRx physician-guided medical weight loss in Columbia and Laurel/Fort Meade, Maryland, alongside functional and preventive medicine, rehabilitation therapies and PREOOP surgical pre-optimization [F]. A reader whose diabetes, kidney disease or retinopathy is already managed by a clinician who knows their full medication list and history may be better served starting that conversation there, because those factors shape medication choice [1, 6, 7]. A reader whose plan covers weight management medication may find the insured route fits better than paying cash [1]. For readers whose main constraint is cost, one model found naltrexone-bupropion cost saving and a review found phentermine/topiramate economically competitive, although tirzepatide produced larger modeled health gains [3, 4]. NIDDK also lists referral to a bariatric surgeon among the options when medication is not enough [1].

## Limitations

The US cost-effectiveness evidence here comes from one microsimulation model whose results depend on its assumptions and on net prices in 2023 dollars [4]. The systematic review found heterogeneous, assumption-sensitive results and limited direct comparisons between newer agents [3]. Adverse event counts for compounded products cannot establish causation and are likely incomplete [2]. The editorial reflects expert opinion rather than new data [5]. The drug details come from consumer references rather than peer-reviewed sources [6, 7].

## How to decide: questions to check

- Do my BMI and health history match the criteria NIDDK describes, as confirmed by a clinician [1]?
- Have I asked my insurer whether my plan covers weight management medication, even if I expect to pay cash [1]?
- Which strength and format is prescribed, and how long will each supply last under its discard rules [2, 6, 7]?
- Is the medication a compounded preparation, and is the prescription filled at a state-licensed pharmacy [2]?
- Does the prescriber screen me first and stay available after the medication arrives [2]?
- What is the plan at 12 weeks on the full dose, and what is likely to happen to my weight if I stop [1]?
- Is a lifestyle program part of the plan [1]?
- Have I discussed lower-acquisition-cost agents with a clinician [3, 4]?
- Do I have a procedure under anesthesia coming up that my clinician should know about [7]?

## References

1. National Institute of Diabetes and Digestive and Kidney Diseases. Prescription Medications to Treat Overweight & Obesity - NIDDK. Accessed October 5, 2026. https://www.niddk.nih.gov/health-information/weight-management/prescription-medications-treat-overweight-obesity
2. US Food and Drug Administration. FDA’s Concerns with Unapproved GLP-1 Drugs Used for Weight Loss | FDA. Accessed October 5, 2026. https://www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/medications-containing-semaglutide-marketed-type-2-diabetes-or-weight-loss
3. Jurković M, Fajkić A, Faour AK, Momčilović M, Turčić P, Belančić A. Economic evaluations of antiobesity medications: A systematic literature review. Br J Clin Pharmacol. 2026. doi:10.1002/bcp.70825. PMID: 42764443. https://pubmed.ncbi.nlm.nih.gov/42764443/
4. Hwang JH, Laiteerapong N, Huang ES, Kim DD. Lifetime Health Effects and Cost-Effectiveness of Tirzepatide and Semaglutide in US Adults. JAMA Health Forum. 2025;6(3):e245586. doi:10.1001/jamahealthforum.2024.5586. PMID: 40085108. https://pubmed.ncbi.nlm.nih.gov/40085108/
5. Savla R, Van Hoven AM, Pilkington B. Ethical Considerations in the Use of Weight Loss Medications. J Gen Intern Med. 2026;41(3):852-855. doi:10.1007/s11606-025-10026-6. PMID: 41219651. https://pubmed.ncbi.nlm.nih.gov/41219651/
6. WebMD. Mounjaro (Tirzepatide): Uses, Side Effects, Interactions, Pictures, Warnings & Dosing - WebMD. Accessed October 5, 2026. https://www.webmd.com/drugs/mounjaro-tirzepatide
7. WebMD. Zepbound (Tirzepatide): Uses, Side Effects, Interactions, Pictures, Warnings & Dosing - WebMD. Accessed October 5, 2026. https://www.webmd.com/drugs/zepbound-tirzepatide